c-Myc is a transcription factor, meaning that it controls gene activity rather than acting as a conventional enzyme with an obvious drug-binding pocket. It regulates networks involved in cell growth, metabolism, protein production and division. In healthy tissues, c-Myc activity is usually tightly controlled and rises only when cells receive appropriate signals. In many cancers, however, the MYC gene is amplified, overexpressed or functionally deregulated. The resulting excess of c-Myc can push cells into a state of relentless proliferation, but its broad importance in normal biology makes direct inhibition challenging. Scientists have therefore increasingly focused on the proteins that work alongside c-Myc, hoping to disrupt tumor-specific support systems rather than eliminate c-Myc itself.

The researchers turned to photoproximity labeling to search for those support systems. Conventional biochemical techniques often require proteins to be extracted from cells, separated and purified, conditions that can cause weak or transient interactions to disappear. Proximity labeling addresses this problem by marking proteins located within a very small molecular neighborhood of a protein of interest. In the photochemical version, exposure to light activates a labeling catalyst positioned near c-Myc. Short-lived reactive species then attach molecular tags to nearby proteins, creating a chemical record of the local environment. Tagged proteins can subsequently be collected and identified by mass spectrometry, allowing researchers to examine c-Myc’s surroundings even when the interactions are brief, indirect or dependent on the cellular context.

That distinction is important because c-Myc does not operate alone at a single stable molecular site. It moves through the nucleus, binds DNA in cooperation with other transcriptional regulators and recruits complexes that modify chromatin and assemble the machinery needed for gene expression. A protein detected near c-Myc is not automatically a direct binding partner, and proximity labeling cannot by itself prove a physical interaction. It can, however, reveal candidates that conventional affinity-purification approaches may miss. The study used this spatial information as a starting point, identifying SLK among the proteins associated with the c-Myc neighborhood and then investigating whether the relationship had functional consequences in cancer cells.

SLK, or STE20-like kinase, belongs to a family of enzymes that transfer phosphate groups to other proteins. Such phosphorylation events can change a protein’s activity, stability, localization or ability to interact with additional partners. SLK has previously been linked to processes including cell movement, cytoskeletal organization and signaling responses, but its connection to c-Myc places it in a different biological framework. The findings indicate that SLK can act as a co-regulator of c-Myc-dependent programs, helping malignant cells maintain gene-expression patterns associated with growth and survival. Rather than being merely a passive neighbor, SLK appears to contribute to the functional environment that allows c-Myc to exert its oncogenic effects.

The cancer-specific character of the relationship is one of the study’s most significant features. According to the researchers, the c-Myc–SLK regulatory connection is stronger or more consequential in cancer cells than in nonmalignant counterparts. This suggests that tumors may become dependent on a signaling arrangement that normal cells either do not use or can tolerate losing. Such differences are highly valuable in drug development. A treatment aimed at SLK, or at the molecular interface linking SLK to c-Myc, might weaken c-Myc-driven tumors while causing less damage to healthy cells than a strategy designed to suppress c-Myc throughout the body. The work does not yet establish a clinically ready therapy, but it identifies a potential point of intervention within a notoriously difficult cancer pathway.

The study also illustrates how spatial proteomics is changing the search for cancer mechanisms. Instead of asking only which proteins can be pulled down with a target under artificial conditions, scientists can ask which proteins occupy its immediate vicinity inside intact cells, and whether that neighborhood changes between normal and malignant states. Light provides an especially useful trigger because labeling can be initiated at a chosen moment and, in principle, restricted to a defined experimental window. This temporal control may help distinguish stable molecular partnerships from short-lived encounters created by signaling, stress or changes in transcriptional activity. Combined with genetic perturbation, imaging, biochemical validation and gene-expression analysis, photoproximity labeling can turn an initially broad list of nearby proteins into a map of functional dependencies.

The findings may also help explain why tumors with similar levels of c-Myc can behave differently. Cancer is not governed by a single oncogene in isolation; the impact of a transcription factor depends on the signaling networks, chromatin landscape and protein partners available in each cell. If SLK supports a particular c-Myc-driven state, tumors with elevated SLK activity could respond differently to therapies than tumors that rely on other co-regulators. Measuring both proteins, or the gene programs controlled by their partnership, might eventually contribute to patient stratification. At present, however, such clinical applications remain speculative. The interaction must be examined across additional tumor types, genetic backgrounds and patient-derived models before its predictive or therapeutic value can be assessed.

Several questions remain open. Researchers will need to determine precisely how SLK influences c-Myc: whether it phosphorylates c-Myc directly, modifies another component of the transcriptional machinery, changes chromatin accessibility or stabilizes a larger regulatory complex. It will also be important to establish whether SLK’s kinase activity is required, or whether the protein can function as a scaffold independent of catalysis. These distinctions matter because an enzymatic dependency may be targeted with a conventional small-molecule inhibitor, whereas a structural interaction could require a different approach, such as a molecular glue, targeted protein degrader or interface-disrupting compound. Future work will also have to clarify how broadly the cancer-specific effect applies and whether blocking the pathway can suppress tumors without triggering compensatory signaling.

For now, the study offers a vivid example of how looking at a cancer protein’s immediate molecular surroundings can uncover biology that remains invisible to standard interaction screens. By illuminating the proteins gathered around c-Myc in living cells, the researchers identified SLK as a potentially important co-regulator and exposed a connection that may be particularly valuable in malignant biology. The result does not make c-Myc an easy target, but it changes the question from how to shut down the transcription factor everywhere to how cancer cells uniquely depend on the machinery surrounding it. That shift could ultimately guide more selective treatments aimed at the support networks that tumors build around their most aggressive growth drivers.

Subject of Research: The cancer-specific molecular regulation of c-Myc and the role of SLK as a co-regulator identified through photoproximity labeling.

Article Title: Photoproximity labeling of c-Myc reveals SLK as a cancer-specific co-regulator.

Article References: Milione, R.R., Tong, F., Wolfe, K.L. et al. Photoproximity labeling of c-Myc reveals SLK as a cancer-specific co-regulator. Nature Chemical Biology (2026). https://doi.org/10.1038/s41589-026-02284-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41589-026-02284-0

Keywords: c-Myc, SLK, cancer biology, photoproximity labeling, proximity proteomics, transcription factors, cancer-specific co-regulators, kinase signaling, molecular oncology, targeted therapy

The study underscores the alarming reality that chemotherapy is often rendered ineffective due to the cancer cells’ ability to adapt and resist treatment. LUSC cells exhibit a robust survival strategy, making the identification of molecular mechanisms like the FXR1-FUBP1 axis essential in understanding and dismantling these defenses. FXR1, a member of the heterogeneous ribonucleoprotein (hnRNP) family, has been implicated in regulating various cellular processes, including RNA metabolism, cell proliferation, and apoptosis. Its interaction with FUBP1, a known regulator of c-Myc, is particularly significant in the context of cancer biology.

In the context of their study, Liang et al. meticulously employed various experimental techniques, including Western blotting and RNA sequencing, to unravel the mechanisms driving chemotherapy resistance. They demonstrated that FXR1 facilitates the stabilization of FUBP1, thus enhancing its interaction with c-Myc mRNA. This stabilization results in increased expression of c-Myc, a pivotal transcription factor that drives cell proliferation and survival, contributing further to chemoresistance observed in LUSC.

The current landscape of chemotherapy effectiveness is grim, with many patients experiencing progression of their disease despite treatment. This stagnation underscores a pressing need for innovative strategies that can sensitize these cancer cells to conventional therapies. The elucidation of the FXR1-FUBP1 axis opens new avenues for targeted therapeutic interventions. By inhibiting FXR1 or disrupting its association with FUBP1, it may be possible to destabilize c-Myc levels, thereby re-sensitizing LUSC cells to chemotherapeutic agents.

Moreover, the implications of this research stretch beyond merely improving clinical outcomes for LUSC patients. It serves as a prototype for similar investigations into other cancer types where chemotherapy resistance poses a significant barrier. The findings emphasize the importance of a molecular approach to understanding tumor biology, prompting researchers and clinicians alike to consider more personalized treatment regimens.

One of the most compelling aspects of this research is the potential for the development of novel therapeutic agents aimed specifically at the components of the FXR1-FUBP1 axis. The targeted inhibition of these proteins could prove to be a game-changer in overcoming the mechanisms responsible for therapy resistance. As our understanding of cancer progresses, the need for precision medicine tailored to individual molecular targets has never been clearer.

The authors of the study further elucidate that targeting the FXR1-FUBP1 axis not only presents a viable strategy for enhancing chemotherapy efficacy but also raises the prospect of repurposing existing drugs used in other contexts. This approach could drastically reduce the time and cost associated with bringing new drugs to market, a significant advantage considering the urgent need for effective cancer therapies.

Emerging technologies such as CRISPR gene editing and RNA interference offer transformative tools that could be harnessed to disrupt the FXR1-FUBP1 interaction. Such advancements could lead to breakthroughs in preclinical and clinical settings, significantly contributing to our arsenal against chemotherapy-resistant LUSC.

As researchers continue to decode the complexities of cellular signaling and gene regulation, collaborations between biologists, pharmacologists, and oncologists will be critical. This multidisciplinary approach will facilitate the translation of laboratory findings into clinical practice, ensuring that discoveries made in the research setting can benefit patients in real-world scenarios.

This study serves as a compelling reminder of the persistent challenges in the realm of oncology. The findings presented by Liang and colleagues underscore the importance of sustained research efforts aimed at understanding the molecular underpinnings of cancer. The fight against LUSC and other malignancies is far from over, but studies like this offer hope and pave the way for innovative strategies that can improve patient outcomes.

In conclusion, the discovery of the FXR1-FUBP1 axis as a key player in chemotherapy resistance in LUSC cells is a significant leap forward in cancer research. These findings not only broaden our understanding of molecular interactions in cancer but also emphasize the urgency of developing therapeutic strategies to tackle this formidable disease. As the fight against cancer continues, every piece of information gained is a step closer to achieving effective treatments and ultimately, saving lives.

Subject of Research: The impact of the FXR1-FUBP1 axis on chemotherapy resistance in lung squamous cell carcinoma (LUSC).

Article Title: The Impact of the FXR1-FUBP1 Axis on Chemotherapy Resistance in LUSC Cells.

Article References:

Liang, R., Li, Y., Chen, J. et al. The Impact of the FXR1-FUBP1 Axis on Chemotherapy Resistance in LUSC Cells.
Biochem Genet (2025). https://doi.org/10.1007/s10528-025-11290-1

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s10528-025-11290-1

Keywords: chemotherapy resistance, LUSC, FXR1, FUBP1, c-Myc, molecular biology, oncology.